Clinical summary
Summary
This is a non-randomised trial that has five experimental arms. In Experimental Arm A, participants will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion. In Experimental Arm B, participants will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion. In Experimental Arm C, participants will receive talquetamab SC in combination with lenalidomide orally. In Experimental Arm D, participants will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally. In Experimental Arm E, participants will receive talquetamab SC in combination with pomalidomide orally.Conditions
This trial is treating patients with multiple myeloma.
Cancer
Blood
Age
18+
Trial Acronym
MonumenTAL-2
More information
Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Commercial Sponsor
Janssen Research & Development, LLC
Scientific Title
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma